Skip to main content
. 2021 Nov 15;27(2):418–426. doi: 10.1007/s10147-021-02070-z

Fig. 1.

Fig. 1

Time to PSA progression (a) in all patients and in subgroup analyses by (b) PSA doubling time, c age, d Gleason score, e median PSA at index date, and (f) initial daily dose of enzalutamide. CI confidence interval; HR hazard ratio; NR not reached; PSA prostate-specific antigen